Nowak Frédérique, Calvo Fabien, Soria Jean-Charles
From the Department of Research and Innovation, Institut National du Cancer, Boulogne-Billancourt, France; SITEP, Department of Medicine, Institut Gustave-Roussy, Villejuif, France.
Am Soc Clin Oncol Educ Book. 2013:332-7. doi: 10.14694/EdBook_AM.2013.33.332.
Drug approvals for molecularly stratified tumor subgroups make molecular testing mandatory and require that molecular diagnostics be performed nationwide. To this end, the French National Cancer Institute (INCa) and the French Ministry of Health have set up a national network of 28 regional molecular genetics centers. Selective molecular tests are performed in these facilities. They are free of charge for all patients in their region, irrespective of the type of establishment in which they are receiving treatment. A specific program has also been implemented to anticipate the launch of new targeted therapies and to accelerate the time-to-access to new drugs and experimental therapies. The initiative has been operational for 5 years and has been successful in meeting its initial aims of uniform nationwide test provision and fast implementation of molecular tests for new tumor biomarkers.
针对分子分层肿瘤亚组的药物批准使分子检测成为强制性要求，并规定必须在全国范围内进行分子诊断。为此，法国国家癌症研究所（INCa）和法国卫生部建立了一个由28个区域分子遗传学中心组成的全国性网络。在这些机构中进行选择性分子检测。对所在区域的所有患者免费，无论他们接受治疗的机构类型如何。还实施了一项特定计划，以预期新靶向疗法的推出，并加快获得新药和实验性疗法的时间。该倡议已实施5年，成功实现了其最初目标，即在全国范围内统一提供检测，并快速实施针对新肿瘤生物标志物的分子检测。
